[go: up one dir, main page]

WO2003101377A3 - Association des polymorphismes mononucleotidiques dans le locus dgcr2 et les locus voisins avec la schizophrenie - Google Patents

Association des polymorphismes mononucleotidiques dans le locus dgcr2 et les locus voisins avec la schizophrenie Download PDF

Info

Publication number
WO2003101377A3
WO2003101377A3 PCT/IL2003/000464 IL0300464W WO03101377A3 WO 2003101377 A3 WO2003101377 A3 WO 2003101377A3 IL 0300464 W IL0300464 W IL 0300464W WO 03101377 A3 WO03101377 A3 WO 03101377A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
dgcr2
locus
snps
association
Prior art date
Application number
PCT/IL2003/000464
Other languages
English (en)
Other versions
WO2003101377A2 (fr
Inventor
Ariel Darvasi
Naomi Zak
Original Assignee
Idgene Pharmaceuticals Ltd
Ariel Darvasi
Naomi Zak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idgene Pharmaceuticals Ltd, Ariel Darvasi, Naomi Zak filed Critical Idgene Pharmaceuticals Ltd
Priority to AU2003231897A priority Critical patent/AU2003231897A1/en
Publication of WO2003101377A2 publication Critical patent/WO2003101377A2/fr
Publication of WO2003101377A3 publication Critical patent/WO2003101377A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des procédés et à des kits utilisés pour déterminer la prédisposition et/ou le diagnostic de la schizophrénie, au moyen de génotypes dans le locus DGCR2. Cette invention concerne également des procédés et des médicaments servant à traiter la schizophrénie, ainsi que des procédés et des kits servant à prédire la réaction du sujet à des médicaments contre les troubles mentaux et, plus spécifiquement, la réaction du sujet à des médicaments contre la schizophrénie.
PCT/IL2003/000464 2002-06-03 2003-06-03 Association des polymorphismes mononucleotidiques dans le locus dgcr2 et les locus voisins avec la schizophrenie WO2003101377A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003231897A AU2003231897A1 (en) 2002-06-03 2003-06-03 Association of snps in the dgcr2 locus and neighboring loci with schizophrenia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38441302P 2002-06-03 2002-06-03
US60/384,413 2002-06-03

Publications (2)

Publication Number Publication Date
WO2003101377A2 WO2003101377A2 (fr) 2003-12-11
WO2003101377A3 true WO2003101377A3 (fr) 2005-01-27

Family

ID=29712028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000464 WO2003101377A2 (fr) 2002-06-03 2003-06-03 Association des polymorphismes mononucleotidiques dans le locus dgcr2 et les locus voisins avec la schizophrenie

Country Status (2)

Country Link
AU (1) AU2003231897A1 (fr)
WO (1) WO2003101377A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118848A1 (fr) * 2004-06-04 2005-12-15 Novartis Ag Biomarqueurs de prediction de la reactivite au traitement a la clozapine
EP2231871B1 (fr) * 2008-01-02 2012-06-27 Suregene LLC Marqueurs génétiques de maladie mentale
EP2231872B1 (fr) * 2008-01-17 2013-04-17 Suregene Llc Marqueurs génétiques de maladie mentale et pour la prédiction de la sensibilité a la perphénazine
US7932042B1 (en) 2010-10-13 2011-04-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE SNP [online] 9 June 2004 (2004-06-09), accession no. NCBI Database accession no. rs807759 *

Also Published As

Publication number Publication date
WO2003101377A2 (fr) 2003-12-11
AU2003231897A1 (en) 2003-12-19
AU2003231897A8 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
WO2003070082A3 (fr) Utilisation de polymorphismes de nucleotides simples dans le locus comt et dans les loci voisins pour determiner une predisposition a la schizophrenie, au trouble bipolaire, au cancer du sein et au cancer colorectal
CA3048093A1 (fr) Polymorphismes nucleotides simples associes a des troubles cardiovasculaires et a une reponse au medicament, leurs procedes de detection et d'utilisation
AU2003299817A1 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
WO2006063704A3 (fr) Polymorphisme a simple nucleotide (snp)
WO2009059317A3 (fr) Prédiction d'amd avec snps à l'intérieur ou près de c2, facteur b, plekha1, htra1, prelp ou loc387715
AU2003257110A1 (en) Polymorphisms for predicting disease and treatment outcome
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2003065000A3 (fr) Procedes de validation de snp et de compilation de banques de dosages
WO2003038123A3 (fr) Procede de traitement du diabete et conditions apparentees basees sur des polymorphismes dans le gene tcf1
AU2003201817A1 (en) Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats
WO2002072604A3 (fr) Genes et polymorphismes associes a une maladie cardiovasculaire et leur utilisation
WO2007006862A3 (fr) Methode et trousse permettant de detecter un risque de coronaropathie
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
WO2003101377A3 (fr) Association des polymorphismes mononucleotidiques dans le locus dgcr2 et les locus voisins avec la schizophrenie
WO2006028999A3 (fr) Evaluation de polymorphismes ctla-4 dans une therapie de blocage de ctla-4
WO2004110365A3 (fr) Compositions et methodes destinees au traitement de maladies hepatiques
WO2005072151A3 (fr) Marqueurs genetiques apoe associes a l'age de l'apparition de la maladie d'alzheimer
WO2005054810A3 (fr) Genotypes cd24 polymorphes indicateurs d'un risque et d'une progression de sclerose en plaques
WO2006063703A3 (fr) Polymorphisme a simple nucleotide (snp)
AU2003250033A1 (en) Genes associated with schizophrenia, adhd and bipolar disorders
WO2005112568A3 (fr) Marqueurs haplotypes et procedes d'utilisation de ceux-ci pour determiner la reponse a un traitement
AU2003299867A1 (en) Method for single nucleotide polymorphism detection
WO2005072152A3 (fr) Marqueurs genetiques apoc1 associes a la periode d'apparition de la maladie d'alzheimer
WO2002053018A3 (fr) Procede d'identification et de gestion de l'augmentation des risques de cancer du sein associes a des polymorphismes des genes mhc
FR2798138B1 (fr) Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP